Zusammenfassung
Der Morbus Behçet ist eine Systemerkrankung mit dem histologischen Korrelat einer leukozytoklastischen Vaskulitis. Pathogenetisch werden neben einer starken genetischen Komponente eine Beteiligung des angeborenen Immunsystems sowie auch eine autoinflammatorische Komponente diskutiert. Die Erkrankung ist am häufigsten in Ländern entlang der früheren Seidenstraße, in Deutschland ist die Erkrankung dagegen selten. Hauptsymptome sind orale Aphthen und Hautmanifestationen, gefolgt von genitalen Aphthen und einer Oligoarthritis der großen Gelenke. Schwerwiegende Manifestationen sind die gastrointestinale Manifestation mit Perforationsneigung, die arteriellen, vor allem pulmonalarteriellen Aeurysmen, die ZNS-Manifestationen und die Augenbeteiligung. Therapeutisch kommen bei leichten Krankheitsmanifestationen niedrig dosierte Steroide und Colchicin zum Einsatz, bei mittelgradigen Manifestationen Azathioprin und Steroide, alternativ Cyclosporin A und Steroide, bei schweren Manifestationen Interferon-α, TNF-Antagonisten oder Zytostatika. In Studien werden aktuell Interleukin-1-Antagonisten erprobt.
Abstract
Behçet’s disease is a systemic disorder with the histopathological correlate of leukocytoclastic vasculitis. Pathogenetically, besides a strong genetic component participation of the innate immune system and an autoinflammatory component are discussed. The disease is most common in countries along the former silk route but in Germany the disease is rare (prevalence approximately 0.6/100,000). Oral aphthous ulcers are the main symptom, followed by skin manifestations, genital ulcers and oligoarthritis of large joints. Severe manifestations, threatening quality of life and even life itself, are the gastrointestinal manifestations which often perforate, arterial, mainly pulmonary arterial aneurysms which cause life-threatening bleeding, CNS manifestations and ocular disease, which with occlusive retinal vasculitis often leads to blindness. For milder manifestations low-dose steroids and colchicine are used, for moderate manifestations such as arthritis or ocular disease not immediately threatening visual acuity, azathioprin or cyclosporin A are combined with steroids. For severe manifestations, interferon-alpha, TNF-antagonists or cytotoxic drugs are recommended. Interleukin 1 (IL-1) antagonists are currently being examined in clinical studies.
Literatur
Behcet H (1937) Über rezidivierende, aphthöse, durch ein Virus verursachte Geschwüre im Mund, am Auge und an den Genitalien. Dermatol Wochenschr 105:1152–1157
Adamantiades B (1930) A case of relapsing iritis with hypopion (in Greek). Archia Iatrikis Etairas (Proceedings of hte Medical Society of Athens):586–539
Deuter CM, Kotter I, Wallace GR et al (2008) Behcet’s disease: ocular effects and treatment. Prog Retin Eye Res 27:111–136
Mizuki N, Meguro A, Ota M et al (2010) Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Behcet’s disease susceptibility loci. Nat Genet 42:703–706
Remmers EF, Cosan F, Kirino Y et al (2010) Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behcet’s disease. Nat Genet 42:698–702
Direskeneli H (2006) Autoimmunity vs autoinflammation in Behcet’s disease: Do we oversimplify a complex disorder? Rheumatology (Oxford) 45:1461–1465
Hatemi G, Bahar H, Uysal S et al (2004) The pustular skin lesions in Behcet’s syndrome are not sterile. Ann Rheum Dis 63:1450–1452
Moll JM, Haslock I, Macrae IF et al (1974) Associations between ankylosing spondylitis, psoriatic arthritis, Reiter’s disease, the intestinal arthropathies, and Behcet’s syndrome. Medicine (Baltimore) 53:343–364
Yurdakul S, Yazici H, Tuzun Y et al (1983) The arthritis of Behcet’s disease: a prospective study. Ann Rheum Dis 42:505–515
Hatemi G, Fresko I, Tascilar K et al (2008) Increased enthesopathy among Behcet’s syndrome patients with acne and arthritis: an ultrasonography study. Arthritis Rheum 58:1539–1545
Leiba M, Sidi Y, Gur H et al (2001) Behcet’s disease and thrombophilia. Ann Rheum Dis 60:1081–1085
Hamuryudan V, Er T, Seyahi E et al (2004) Pulmonary artery aneurysms in Behcet syndrome. Am J Med 117:867–870
Al-Araji A, Kidd DP (2009) Neuro-Behcet’s disease: epidemiology, clinical characteristics, and management. Lancet Neurol 8:192–204
Horger M, Maksimovic O, Kotter I et al (2008) Neuro-Behcet’s disease: MR-imaging findings. Rofo 180:691–697
Kotter I, Deuter C, Gunaydin I et al (2006) MAGIC or not MAGIC – does the MAGIC (mouth and genital ulcers with inflamed cartilage) syndrome really exist? A case report and review of the literature. Clin Exp Rheumatol 24:S108–112
Khalid U, Saleem T (2011) Hughes-Stovin syndrome. Orphanet J Rare Dis 6:15
Anonymous (1990) Criteria for diagnosis of Behcet’s disease. International Study Group for Behcet’s Disease. Lancet 335:1078–1080
Dilsen N, Konice M, Aral O (1985) Our diagnostic criteria of Behcet’s disease – an overview. In: Lehner T, Barnes CG (Hrsg) Recent advances in Behcet’s disease. Royal Society of Medicine Services, London, S 177–180
Mason RM, Barnes CG (1969) Behcet’s syndrome with arthritis. Ann Rheum Dis 28:95–103
O’Duffy JD (1974) Critères proposés pour le diagnostic de la maladie de Behcet. Rev Med 36:2371–2379
Mizushima Y (1988) Revised diagnostic criteria for Behcet’s disease in 1987. Ryumachi 28:66–70
Hatemi G, Silman A, Bang D et al (2008) EULAR recommendations for the management of Behcet disease. Ann Rheum Dis 67:1656–1662
Arida A, Fragiadaki K, Giavri E et al (2011) Anti-TNF agents for Behcet’s disease: analysis of published data on 369 patients. Semin Arthritis Rheum 41:61–70
Kotter I, Gunaydin I, Zierhut M et al (2004) The use of interferon alpha in Behcet disease: review of the literature. Semin Arthritis Rheum 33:320–335
Deuter CM, Zierhut M, Mohle A et al (2010) Long-term remission after cessation of interferon-alpha treatment in patients with severe uveitis due to Behcet’s disease. Arthritis Rheum 62:2796–2805
Kotter I, Gunaydin I, Batra M et al (2006) CNS involvement occurs more frequently in patients with Behcet’s disease under cyclosporin A (CSA) than under other medications – results of a retrospective analysis of 117 cases. Clin Rheumatol 25:482–486
Ando K, Fujino Y, Hijikata K et al (1999) Epidemiological features and visual prognosis of Behcet’s disease. Jpn J Ophthalmol 43:312–317
Interessenkonflikt
Der korrespondierende Autor gibt für sich und seine Koautoren an, dass kein Interessenkonflikt besteht.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kötter, I., Xenitidis, T., Fierlbeck, G. et al. Morbus Behçet. Z. Rheumatol. 71, 685–697 (2012). https://doi.org/10.1007/s00393-012-1012-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00393-012-1012-x